Compare Halliburton Company (HAL) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halliburton Company vs Zoetis Inc — how do they compare? Halliburton Company trades at $32.61 (market cap $27.14B), while Zoetis Inc trades at $74.35 (market cap $30.20B). The key difference: Halliburton Company and Zoetis Inc are close in size by market cap, and Zoetis Inc pays the higher dividend (2.9%). Which is the better fit depends on your goals — on Pluang, investors hold Halliburton Company for 89 Days and Zoetis Inc for 70 Days on average.
| HAL | ZTS | |
|---|---|---|
Market Cap | $27.14B | $30.20B |
Volume | 11,258,156 | 6,175,327 |
Sector | Energy | Health |
52-Week High | $42.98 | $147.53 |
52-Week Low | $21.82 | $69.09 |
Typical Hold Time | 89 Days | 70 Days |
Enterprise Value | $33.29B | $37.76B |
Dividend Yield | 2.09% | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Halliburton (HAL) trades at $31.75, down 2.96% on the day, reflecting near-term bearish technical signals despite strong analyst support. The stock shows solid fundamentals with a P/E of 17.05 and consistent earnings beats in recent quarters. Recent news highlights expansion in Venezuela and a new contract in Cyprus, positioning the company for growth in international energy markets. Cash flow trends indicate variability, with 2025 net cash flow negative but projected to turn positive in 2026.
The outlook for HAL is cautiously optimistic, driven by international contracts and analyst consensus pointing to significant upside with a $43.11 price target. Key risks include oil price volatility and execution challenges in new markets. Investment opportunity lies in the company's strategic expansions and robust profitability metrics, though investors should weigh macroeconomic factors affecting the energy sector.
Zoetis (ZTS) trades at $71.55, showing modest daily gains of 0.32% amid a challenging market environment. The stock faces bearish technical signals with mixed earnings performance, having beaten estimates in Q2 2026 but missing in Q1. Despite recent headwinds in U.S. companion animal sales, the company maintains strong profitability with 71.67% gross margins and 27.69% net income margins. Analyst consensus remains positive with a $87.33 price target, though technical indicators suggest near-term pressure with support at $70-$71.
Zoetis presents a compelling value opportunity with attractive valuation multiples (P/E 11.92, EV/EBITDA 9.4) and robust fundamentals, though near-term risks include competitive pressures in pet medications and weakening U.S. veterinary clinic traffic. The company's international and livestock segments show resilience, supporting long-term growth potential despite current market skepticism.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Halliburton Company
Halliburton is one of the three largest oilfield service firms in the world, offering superior expertise in a number of business lines, including completion fluids, wireline services, cementing, and countless others. It's the number one pressure pumper in North America, and has been a leading innovator in hydraulic fracturing over the last two decades.
Read more on HAL →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
